Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
FDA
Articles
FDA says ‘not yet’ on Lilly’s once-weekly Byetta
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Lilly settles Arkansas Zyprexa suit for $18.5M
Arkansas Attorney General Dustin McDaniel on Tuesday announced an $18.5 million settlement of a lawsuit with Eli Lilly &
Co. over off-label marketing of the anti-psychotic drug Zyprexa.
Pfizer’s Viagra patent partially rejected in Lilly fight
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
Lilly shares get boost from OK of rival’s drug
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators’
clearance of a similar drug.
Biotech firm plans $28M Greenwood plant
Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
FDA letters scold Lilly, others over marketing materials
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
FDA cancels meeting to review Lilly’s Cymbalta
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Pfizer to pay record $2.3B penalty over promotions
Pfizer Inc., the world’s largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription
drug promotions, the Justice Department announced today.
POWER BREAKFAST: Panel applauds progress, identifies challenges
A panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
BREAKING: FDA approves Lilly blood-thinner prasugrel
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Lilly asks FDA to review weekly diabetes drug
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Lilly cancer drug OK’d for new use
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Commercializing science takes too long, Cook says
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Generic meds cost more than consumers realize
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Lilly expects FDA approval of long-acting version of Zyprexa
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.